首页> 中文期刊> 《中国医药导刊》 >眩晕宁与苯磺酸倍他司汀联合治疗椎基底动脉供血不足性眩晕临床观察

眩晕宁与苯磺酸倍他司汀联合治疗椎基底动脉供血不足性眩晕临床观察

         

摘要

Objective: To observe the Xuanyunning tablet and acid combination therapy betahistine vertebrobasilar insufficiency vertigo efficacy and safety. Methods: 90 patients with vertebrobasilar insufficiency vertigo were randomly divided into treatment group and control group, treatment group Xuanyunning tablets combined betahistine acid treatment, the control group received acid betahistine statin monotherapy. Results: The total effective rate of 95.56% in the control group, the total effective rate was 71.11%, the difference was statistically signiifcant. Improvement rate transcranial Doppler (TCD) examination showed that the treatment group than the control group (P<0.05). Groups no serious adverse reactions between the two groups was not statistically signiifcant. Conclusion:Xuanyunning combined acid betahistine treatment of vertebral basilar artery insufifciency was signiifcantly higher than the efifcacy of betahistine acid monotherapy.%目的:观察眩晕宁与苯磺酸倍他司汀联合治疗椎基底动脉供血不足性眩晕的疗效及安全性。方法:将90例椎基底动脉供血不足性眩晕的患者,随机分成治疗组和对照组,治疗组应用眩晕宁薄膜衣片联合苯磺酸倍他司汀治疗,对照组应用苯磺酸倍他司汀单药治疗。结果:治疗组总有效率95.56%,对照组总有效率为71.11%,两组比较差异具有统计学意义。改善率经颅多普勒超声(TCD)检查显示,治疗组明显优于对照组(P<0.05)。两组均未发生严重不良反应,组间比较无统计学意义。结论:眩晕宁联合苯磺酸倍他司汀治疗椎基底动脉供血不足的疗效明显高于苯磺酸倍他司汀单药治疗。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号